semaglutide nejm weight loss Tirzepatide vs for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% at 72 wks • Semaglutide: −13.7% • Greater waist reduction Weight loss with semaglutide reduces
Description
CrossRef Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya Naunyn-Schmiedeberg's Archives of Pharmacology.2024
The specific physiological mechanisms of ejaculatory dysfunction remain unclear, and there is a lack of research on how neuropathy specifically affects the ejaculation process
Appetite Regulation: GLP-1 functions to enhance the sensation of being full
The RESTORE trial remains actively recruiting and tracking participants to enrich the data pool and further elucidate dose-response relationships and safety profiles
they provide a glimpse into the next frontier of obesity care
